Format

Send to

Choose Destination
See comment in PubMed Commons below
MAbs. 2012 Mar-Apr;4(2):233-42. doi: 10.4161/mabs.4.2.19262. Epub 2012 Mar 1.

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Author information

1
Laboratory of Viral Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, MD USA.
2
Departiment of Microbiology and Immunology; Rosalind Franklin University of Medicine and Science; Chicago, IL USA.

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV, human herpesvirus 8) is etiologically associated with three neoplastic syndromes: Kaposi sarcoma and the uncommon HIV-associated B-cell lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman disease. The incidence of the latter B-cell pathology has been increasing in spite of antiretroviral therapy; its association with lytic virus replication has prompted interest in therapeutic strategies aimed at this phase of the virus life cycle. We designed and expressed a recombinant immunotoxin (2014-PE38) targeting the gpK8.1A viral glycoprotein expressed on the surface of the virion and infected cells. We show that this immunotoxin selectively kills KSHV-infected cells in dose-dependent fashion, resulting in major reductions of infectious virus release. The immunotoxin and ganciclovir, an inhibitor of viral DNA replication, showed marked reciprocal potentiation of antiviral activities. These results suggest that the immunotoxin, alone or in combination, may represent a new approach to treat diseases associated with KSHV lytic replication.

KEYWORDS:

KSHV lytic infection; KSHV surface glycoprotein; Pseudomonas exotoxin A; ganciclovir; human herpesvirus-8; multicentric Castleman disease; reciprocal drug potentiation; targeted cytotoxic proteins

PMID:
22377676
PMCID:
PMC3361659
DOI:
10.4161/mabs.4.2.19262
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center